Novel Cancer Drug Therapies | Immunotherapy & NSCLC | Cancer Patient Immune ResponseJune 02, 2021 | Oncology Hematology Assessment of New Molecular Entities Approved for Cancer Treatment in 2020 Despite the pandemic interrupting trials and drug development in 2020, the US Food and Drug Administration (FDA) claims it is “full speed ahead” on the approval of novel cancer drug therapies. The authors of this Journal of the American Medical Association (JAMA) study wanted to verify these remarks, reviewing the FDA Hematology/Oncology Approvals website to ascertain all hematology/oncology drugs approved in 2020. Read full article Geriatrics Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer In this JAMA Original Investigation, the researchers studied 19,529 patients with Medicare coverage who initiated first systemic therapy for advanced non–small cell lung cancer (NSCLC) using 1 of 4 regimens of checkpoint inhibitor immunotherapy, cytotoxic chemotherapy, and combined chemoimmunotherapy. The goal? To gauge the uptake and effectiveness of immunotherapy among older patients outside clinical trials. Read full article Allergy & Immunology Immune Responses to SARS-CoV-2 Among Patients With Cancer In this issue of JAMA Oncology, two groups investigate the immune response to SARS-CoV-2, by proxy of antibody assays, in patients with solid malignant neoplasms who were undergoing active cancer therapy. With the concern that patients with cancer may not mount a robust protective immune response to SARS-CoV-2 infection or vaccination, the studies attempt to discover what seropositivity can tell us. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS